Efficacy and Safety of Vutrisiran in Patients with Hereditary Transthyretin-mediated Amyloidosis with Polyneuropathy: Analysis of the East Asian Subpopulation from HELIOS-A
Although the number of East Asian patients in HELIOS-A was small, this post hoc analysis showed similar outcomes to those in the overall study populations, indicating that vutrisiran is effective and well tolerated in East Asian patients.
Authors
- Jeeyoung Oh
- Amy Chan-Daniels
- CT Tan
- Yi-Chung Lee
- Yohei Misumi
- Weizhi Zhao
- Ju-Hong Min
- Yoshiki Sekijima
- Chi-Chao Chao
- Masahisa Katsuno
- Hideki Mochizuki
Institutions
- Shinshu University (JP)
- Alnylam Pharmaceuticals (United States) (US)
- Samsung Medical Center (KR)
- Taipei Veterans General Hospital (TW)
- University of Malaya (MY)
- Konkuk University Medical Center (KR)
- Toneyama National Hospital (JP)
- National Taiwan University Hospital (TW)
- Nagoya University (JP)
- Sungkyunkwan University (KR)
- Kumamoto University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1007/s40120-026-00899-y
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Alnylam Pharmaceuticals